970

EQS-News: Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test

Retrieved on: 
Monday, September 19, 2022
ECX, Risk, PMA, FDA, Food, AG, Liquid biopsy, Blood, Biomarker, News, Colorectal cancer, CRC, 970, OTCQX, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, Physician, EQS, CEO, Technology, Clinical, DNA, Communication, Epigenomics AG, Security (finance), Pharmaceutical industry, Epigenomics

The prospective, multi-center study titled CRC-DRAW (CRC-Detection Reliable Assessment With Blood) will enroll screening eligible participants 45 years of age and older who are at average risk for colorectal cancer.

Key Points: 
  • The prospective, multi-center study titled CRC-DRAW (CRC-Detection Reliable Assessment With Blood) will enroll screening eligible participants 45 years of age and older who are at average risk for colorectal cancer.
  • Over the course of the trial, it is expected to enroll over 15,000 subjects to achieve the proposed statistical endpoints needed for the study.
  • Epigenomics AG is a molecular diagnostics company focused on blood testing for the early detection of cancer.
  • Epigenomics' lead product is the blood test Epi proColon for the early detection of colorectal cancer.

DGAP-News: Epigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktG

Retrieved on: 
Monday, August 15, 2022
Epigenomics AG, Board of directors, DGAP, AG, ECX, Company, SEC, Judgement, News, 970, Epigenomics, RTÉ Executive Board, OTCQX, Security (finance)

Epigenomics AG: Notice of Loss pursuant to Sec.

Key Points: 
  • Epigenomics AG: Notice of Loss pursuant to Sec.
  • 92 par.
  • 1 AktG
    The issuer is solely responsible for the content of this announcement.
  • Epigenomics AG: Notice of Loss pursuant to Sec.

DGAP-News: ​​​​​​​Epigenomics AG Reports Financial Results for the First Six Months of 2022

Retrieved on: 
Wednesday, August 10, 2022
FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Centers for Medicare & Medicaid Services, FSE, Epigenomics AG, CEO, Center for Medicare and Medicaid Innovation, Medicare, Legislation, Board of directors, Technology, CE marking, EUR, Clinical trial, Cancer, Center, DGAP, Congress, AG, Method, ECX, Marketing, EBITDA, DNA, Company, Next Generation, CET, News, IFRS, CMS, General officer, Research, Webcast, Liver cancer, COVID-19, Goal, Section 92 of the Constitution of Australia, EDT, Colorectal cancer, 970, Administration, Food, OTCQX, Security (finance), Renewable energy, Film, Cryptocurrency, Pharmaceutical industry, Audit, Epigenomics

Berlin (Germany) and San Diego, CA (U.S.A.), August 10, 2022 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the second quarter and first half of 2022.

Key Points: 
  • Berlin (Germany) and San Diego, CA (U.S.A.), August 10, 2022 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the second quarter and first half of 2022.
  • Epigenomics AG assumes that given the planned financial development, a cumulative loss of more than half of the nominal share capital will occur in the near future.
  • The interim statement for the first six months 2022 (unaudited) can be found on Epigenomics' website at: https://www.epigenomics.com/news-investors/financial-reports/ .
  • Epigenomics AG will host a conference call for analysts and investors today at 4.00 pm (CET) / 10.00 am (EDT).

DGAP-News: Epigenomics AG Reports Financial Results for the First Quarter of 2022

Retrieved on: 
Wednesday, May 11, 2022
970, Medicare, Email, EBITDA, DGAP, Company, Food, Legislation, EUR, CE marking, Clinical trial, FDA, Cancer, Liver cancer, Regulation of tobacco by the U.S. Food and Drug Administration, AG, DNA, ISIN, IFRS, Colorectal cancer, Marketing, News, ECX, Goal, CEO, Technology, FSE, Epigenomics AG, OTCQX, Security (finance), Film, Pharmaceutical industry, Audit, Epigenomics, U.S.A

Berlin (Germany) and San Diego, CA (U.S.A.), May 11, 2022 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first three months of 2022.

Key Points: 
  • Berlin (Germany) and San Diego, CA (U.S.A.), May 11, 2022 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first three months of 2022.
  • Revenues in the first quarter 2022 increased slightly from EUR 106 thousand to EUR 115 thousand compared to the prior-year period.
  • Cash consumption increased to EUR 3,408 thousand in the first quarter of 2022 (Q1 2021: EUR 2,386 thousand).
  • As of March 31, 2022, the Company had cash and cash equivalents of EUR 20,039 thousand (December 31, 2021: EUR 23,049 thousand).

DGAP-News: ​​​​​​​Epigenomics AG Reports Financial Results for Fiscal Year 2021

Retrieved on: 
Friday, April 1, 2022
People, EBITDA, Total, Company, FSE, Next Generation, CET, Cancer Breakthroughs 2020, DNA, Sale, Marketing, OTCQX, Biobank, Clinical trial, Legislation, Colorectal cancer, News, CFO, DGAP, Epigenomics AG, Program, EDT, CMS, Centers for Medicare & Medicaid Services, Cancer, Webcast, Board of directors, CEO, Food, 970, Federal Executive Boards, CE marking, CRC, Person of color, Technology, Goal, Annual, Liver cancer, ECX, COVID-19, Regulation of tobacco by the U.S. Food and Drug Administration, Center, Medicare, AG, EUR, Annual report, FDA, Email, Blood, Nextgen, IFRS, Security (finance), Film, Pharmaceutical industry, Dietary supplement, Online shopping, Color, U.S.A, Epigenomics

In 2021, Epigenomics started preparations for the FDA clinical trial for the Company's Epi proColon "Next-Gen" test.

Key Points: 
  • In 2021, Epigenomics started preparations for the FDA clinical trial for the Company's Epi proColon "Next-Gen" test.
  • In 2021, the Company has also focused on maximizing its financial position to enable the development of the Epi proColon "Next-Gen" test.
  • Cash consumption improved to EUR -4.2 million in fiscal year 2021 compared to EUR -9.6 million in 2020.
  • Epigenomics AG will host a conference call for analysts and investors today at 4.00 pm (CET) / 11.00 am (EDT).

DGAP-News: Supervisory Board of Epigenomics AG Retains Greg Hamilton as Chief Executive Officer Through Development of Epi proColon 'Next-Gen' Colorectal Cancer Screening Test

Retrieved on: 
Monday, January 24, 2022
CMS, CE marking, Liver cancer, Technology, Bachelor of Science, Supervisory board, Hologic, Center, Colorectal cancer, Clinical trial, CRC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MBA, Next Generation, CEO, OTCQX, Third wave, AG, Email, Chicago (franchise), DNA, Epigenomics AG, NCD, DGAP, Liquid biopsy, Marketing, Medicare, News, Purdue University, Centers for Medicare & Medicaid Services, Cancer, Food, Communication, Human papillomavirus infection, HPV, ECX, FDA, 970, National coverage determination, University, Security (finance), Pharmaceutical industry, Risk management, Epigenomics, Science, Operation

Appointment underscores Epigenomics' commitment to the company's enhanced blood-based colorectal cancer screening test, Epi proColon "Next-Gen", which provides a large untapped opportunity in the cancer screening market

Key Points: 
  • Appointment underscores Epigenomics' commitment to the company's enhanced blood-based colorectal cancer screening test, Epi proColon "Next-Gen", which provides a large untapped opportunity in the cancer screening market
    Berlin (Germany) and San Diego, CA (U.S.A.), January 24, 2022 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, announced today that the Supervisory Board retained Greg Hamilton as Chief Executive Officer through December 31, 2025.
  • Mr. Hamilton has been CEO of Epigenomics AG since mid-2016 and will continue to lead the company through the development, FDA approval and commercialization of the company's Epi proColon "Next-Gen" Colorectal Cancer (CRC) screening test.
  • Epigenomics AG is a molecular diagnostics company focused on blood testing for the early detection of cancer.
  • Epigenomics' lead product is the blood test Epi proColon(R) for the early detection of colorectal cancer.

DGAP-News: ​​​​​​​Supervisory Board of Epigenomics AG appoints Jens Ravens as Chief Financial Officer

Retrieved on: 
Monday, December 20, 2021
Investment banking, Technology, Food, EPI, FDA, Supervision, Deutsche Bank, University of Fribourg, INSEAD, RTÉ Executive Board, Supervisory board, OTCQX, Colorectal cancer, Otto, Email, Cancer, DGAP, CDI, Compliance, Hermes Group, Epigenomics AG, News, Regulation of tobacco by the U.S. Food and Drug Administration, Marketing, ECX, CFO, DNA, CE marking, 970, University, Liver cancer, Board of directors, AG, Communication, Security (finance), Risk management, Management, Epigenomics

Jens Ravens is an internationally experienced leader with in-depth experience in Controlling, Finance, M&A, IT, Legal, and Human Resources

Key Points: 
  • Jens Ravens is an internationally experienced leader with in-depth experience in Controlling, Finance, M&A, IT, Legal, and Human Resources
    New Chief Financial Officer to join Epigenomics on February 1, 2022
    Berlin (Germany) and San Diego, CA (U.S.A.), December 14, 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company"), an oncology focused molecular diagnostics company, announced today that the Supervisory Board appointed Jens Ravens as Chief Financial Officer with effect from February 1, 2022.
  • Jens Ravens, who has extensive financial executive experience will become a member of the Executive Board of Epigenomics and oversee the company's financial and administrative functions.
  • Jens Ravens (52) has over 20 years of management experience in finance in various European companies.
  • Heino von Prondzynski, Chairman of the Supervisory Board: "We are very pleased to have Jens join Epigenomics AG as CFO with his in-depth management experience as well as his extensive expertise in finance.

DGAP-News: ​​​​​​​Supervisory Board of Epigenomics AG Appoints Dr. Andrew Lukowiak as President and Chief Scientific Officer

Retrieved on: 
Monday, November 22, 2021
Research, Automation, Cervical cancer, Regulation of tobacco by the U.S. Food and Drug Administration, CEO, HPV, Technology, Board of directors, Pennsylvania State University, PCR, News, University, Cancer, RTÉ Executive Board, Next Generation, DGAP, Supervisory board, Leadership, Hologic, PMA, Liquid biopsy, Liver cancer, ECX, Epigenomics AG, OTCQX, DNA, EPI, Email, Communication, Colorectal cancer, Marketing, 970, AG, Development, FDA, CE marking, Food, Genetics, Management, Security (finance), Medical device

Supervisory Board of Epigenomics AG Appoints Dr. Andrew Lukowiak as President and Chief Scientific Officer

Key Points: 
  • Supervisory Board of Epigenomics AG Appoints Dr. Andrew Lukowiak as President and Chief Scientific Officer
    The issuer is solely responsible for the content of this announcement.
  • Supervisory Board of Epigenomics AG Appoints Dr. Andrew Lukowiak as President and Chief Scientific Officer
    New President and Chief Scientific Officer to join Epigenomics on December 1, 2021
    Berlin (Germany) and San Diego, CA (U.S.A.), November 18, 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company"), the German-American cancer molecular diagnostics company, announced today that the Supervisory Board appointed Dr. Andrew Lukowiak as President and Chief Scientific Officer with effect from December 1, 2021.
  • Prior to joining Epigenomics, Andrew served as CEO and Board Member for Millennium Health, a leading specialty toxicology laboratory.
  • Heino von Prondzynski, Chairman of the Supervisory Board, stated: "The Supervisory Board is excited to add the significant executive management, clinical and technical expertise that Andrew brings to the Executive Board of Epigenomics AG.

DGAP-News: Epigenomics AG publishes financial results for the first nine months 2021

Retrieved on: 
Wednesday, November 10, 2021
Email, Biobank, Epigenomics AG, Cancer, EPI, CMS, Colorectal cancer, Clinical trial, News, FSE, OTCQX, Technology, CE marking, Food, Liver cancer, Trial of the century, EDT, IFRS, Regulation of tobacco by the U.S. Food and Drug Administration, EBITDA, Sale, Company, Research, 970, ECX, CET, EUR, AG, Webcast, DNA, Marketing, FDA, DGAP, Security (finance), Film, Cryptocurrency, Online shopping, Life insurance

Berlin (Germany) and San Diego, CA (U.S.A.), November 10, 2021 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first nine months of 2021.

Key Points: 
  • Berlin (Germany) and San Diego, CA (U.S.A.), November 10, 2021 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first nine months of 2021.
  • Cash consumption decreased to EUR 3,598 thousand in the first nine months of 2021 (9M 2020: EUR 7,492 thousand).
  • The financial report for the first nine months of 2021 is available on the Epigenomics' website at: https://www.epigenomics.com/news-investors/financial-reports/ .
  • Epigenomics AG will host a conference call for analysts and investors today at 4.00 pm (CET) / 10.00 am (EDT).

DGAP-News: Epigenomics AG: EVP of Finance Albert Weber leaves the Company

Retrieved on: 
Thursday, October 7, 2021
EPI, Food, Email, Regulation of tobacco by the U.S. Food and Drug Administration, DNA, News, FDA, Cancer, Board of directors, DGAP, Liver cancer, RTÉ Executive Board, Marketing, Company, Communication, 970, Technology, Colorectal cancer, Epigenomics AG, AG, CE marking, Supervisory board, ECX, OTCQX, Security (finance)

Berlin (Germany) and San Diego, CA (U.S.A.), October 7, 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that Executive Vice President Finance Albert Weber will resign from his position as member of the Executive Board of Epigenomics AG as of December 31, 2021, to pursue other interests.

Key Points: 
  • Berlin (Germany) and San Diego, CA (U.S.A.), October 7, 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that Executive Vice President Finance Albert Weber will resign from his position as member of the Executive Board of Epigenomics AG as of December 31, 2021, to pursue other interests.
  • Albert Weber will remain available to the Company in an advisory capacity until June 30, 2022.
  • Epigenomics AG is a molecular diagnostics company focused on blood testing for the early detection of cancer.
  • Epigenomics' lead product is the blood test Epi proColon(R) for the early detection of colorectal cancer.